Botulax vs Botox | Price, Purity, and Performance Comparison
American Botox holds an advantage in stability thanks to its patented vacuum-drying technology, with an average price of approximately 3,000 RMB;
Meanwhile, South Korean Botulax has become a high-performance-to-price alternative due to its purity of over 99% and a price approximately 50% of the former.
Both products provide stable clinical results that last for 4 to 6 months.
Price
In a comparison of the 100U specification, the market wholesale price of Botulax typically ranges between $150 and $250, while the procurement cost for the same specification of Botox remains stable at $500 to $600.
Since both follow a 1:1 conversion ratio in clinical applications, using Botulax can reduce the expenditure on materials by more than 50% for the same treatment area.
Average Market Retail Price
Taking medical aesthetic clinics in New York and Los Angeles as examples, the retail price per unit of Botox is usually maintained between $12 and $25, while the price per unit for the equivalent Botulax is often set between $8 and $14.
This price difference becomes particularly pronounced in large-dose injections of 100U.
Typically, the wholesale cost for a doctor to purchase a 100U vial of Botox is approximately $570 to $620.
Combined with clinic rent, insurance, medical supplies, and labor costs, the total fee paid by the end-user for a vial of Botox often reaches $1,200 to $2,000.
In contrast, the wholesale procurement price for Botulax is only around $140 to $180, which allows clinics to maintain profits while offering users full-vial 100U packages priced between $600 and $900.
| Region/Indicator | Botox (100U) Avg. Retail Price | Botulax (100U) Avg. Retail Price | Price Difference Per Unit |
|---|---|---|---|
| North America (USA/Canada) | $1,200 – $1,800 | $700 – $1,000 | $5 – $10 |
| Europe (UK/EU) | £350 – £550 | £180 – £280 | £3 – £6 |
| Southeast Asia (Thailand/Vietnam) | $400 – $600 | $150 – $300 | $2 – $5 |
| CIS (Russia/Ukraine) | $250 – $450 | $100 – $200 | $1.5 – $3 |
At Harley Street clinics in London, UK, per-area billing is the mainstream. The cost for a typical forehead or crow’s feet treatment using Botox is approximately £200 to £350, while the cost using Botulax can be as low as £120 to £220.
Based on a standard injection volume of 20U, the cost per procedure for Botox is approximately $300 to $500, whereas the same procedure with Botulax only costs $160 to $300.
This price advantage is further magnified in body contouring projects that require large doses.
For example, calf muscle reduction or shoulder line optimization usually requires a dose of 100U to 200U.
Users choosing Botox may need to pay $2,400 to $4,000, while those choosing Botulax only pay $1,200 to $1,800.
The amount saved is enough to provide users with multiple subsequent maintenance treatments.
| Treatment Project | Required Dose (Standard) | Estimated Botox Cost | Estimated Botulax Cost |
|---|---|---|---|
| Glabellar Lines | 20U | $300 – $500 | $160 – $280 |
| Forehead Lines (Frontalis) | 20U | $280 – $450 | $150 – $260 |
| Crow’s Feet | 24U | $350 – $550 | $200 – $350 |
| Masseter Reduction | 50U | $650 – $1,100 | $350 – $600 |
| Body (Shoulder/Leg) | 100U | $1,200 – $1,800 | $600 – $950 |
As the flagship product of Allergan, Botox’s global supply chain requirements are extremely stringent.
It must be transported at a constant temperature between 2 and 8 degrees Celsius; any temperature excursion will lead to a decline in the drug’s activity.
These high-standard logistics requirements result in cross-border transportation costs that are 15% to 20% higher than ordinary pharmaceutical products.
Although Botulax also requires cold chain transportation, its manufacturer, Hugel, has established a flatter distribution network in Asia and Eastern Europe.
By reducing intermediate agent links, they have lowered circulation costs by approximately 30%.
For users, approximately 40% of the fees paid are to cover these logistics and brand premiums.
In actual outpatient appointments, many doctors offer bundle discounts, such as a free touch-up with the purchase of a 100U package or a 20% discount on membership days.
Because the original cost of Botulax is low, clinics have greater flexibility when formulating promotional strategies. “Buy two, get one free” events are common, allowing the actual expenditure per unit to drop even further to below $6.
The effects of botulinum toxin usually begin to fade 3 to 4 months after injection, and a patient typically needs about 3 injections per year.
For a user receiving comprehensive full-face treatment requiring 50U per session, the total annual budget for Botox would reach $1,800 to $3,000.
If switching to Botulax, the annual budget would drop to between $900 and $1,500.
Over a long-term observation cycle of five years, a user of Botulax can save approximately $4,500 to $7,500 compared to a Botox user.
Although loyal Botox users believe its longer clinical history provides higher safety expectations, from the perspective of pure biological potency and unit expenditure ratio, Botulax’s retail performance in the international market shows strong expansibility.
In aesthetic clinics in many high-inflation regions, Botulax has already become the first choice for over 70% of new users because the financial threshold for a single trial is lower.
Annual Maintenance Expenses
In international clinical observations, the effects of Type A botulinum toxin usually begin to subside 12 to 16 weeks after injection as nerve ending signal transmission gradually recovers.
For users pursuing continuous facial smoothness, 3 to 4 injections per year are usually scheduled.
Based on a single dose of 50 units for the standard three facial areas (forehead, glabellar, and crow’s feet), a Botox user needs to consume 150 to 200 units of the drug annually.
In medical institutions in North America or Australia, the retail price per unit of Botox is generally $15 to $25, which brings the total annual expenditure for materials and procedures to between $2,250 and $5,000.
In contrast, the unofficial price of Botulax in the same regions, or the retail price in legally accessible regions such as Southeast Asia and Eastern Europe, is only $8 to $12 per unit.
Calculation results show that for the same 50-unit dose, the annual maintenance budget for Botulax can be controlled between $1,200 and $2,400.
This nearly two-fold expenditure gap can result in a difference of tens of thousands of dollars over a multi-year maintenance plan.
| Maintenance Project & Dose | Frequency (Per Year) | Estimated Botox Annual Cost (USD) | Estimated Botulax Annual Cost (USD) | Annual Savings Difference (USD) |
|---|---|---|---|---|
| Basic Facial Wrinkles (50U) | 3 Times | $2,250 – $3,750 | $1,200 – $1,800 | $1,050 – $1,950 |
| Basic Facial Wrinkles (50U) | 4 Times | $3,000 – $5,000 | $1,600 – $2,400 | $1,400 – $2,600 |
| Moderate/Severe Masseter (60U) | 2.5 Times | $2,700 – $4,500 | $1,200 – $1,800 | $1,500 – $2,700 |
| Full Face Lift/Micro-droplet (80U) | 3 Times | $3,600 – $6,000 | $1,920 – $2,880 | $1,680 – $3,120 |
| Large Body Muscle Groups (200U) | 2 Times | $6,000 – $10,000 | $3,200 – $4,800 | $2,800 – $5,200 |
In treatments targeting the masseter, trapezius, or gastrocnemius muscles, the required dose per session often starts at 100 units or even reaches 200 units.
Because the metabolism rate of large muscle groups is highly correlated with daily exercise volume, users who are keen on fitness or high-intensity labor may need additional doses every 3 months.
Using Botox for this type of systemic line optimization could lead to an annual consumption of 400 to 600 units, with retail fees exceeding $10,000.
Users choosing Botulax can take advantage of its low unit price to complete the same annual plan with a budget of around $4,000.
Many users typically choose Botox in the first year to verify muscle sensitivity and drug resistance.
However, after entering the long-term maintenance period in the second or third year, about 40% of international users switch to the more cost-effective Botulax for financial sustainability.
In the UK or EU countries, high-end private clinics usually charge a doctor’s consultation fee of £50 to £150 per visit.
If choosing Botox, this fee is usually mandatory and rarely discounted because the brand is often tied to high-end chain clinics.
Botulax’s distribution channels are more concentrated in Medical Spas. To increase turnover and user stickiness, these institutions often launch annual maintenance packages.
For example, a prepayment of $1,500 might grant unlimited Botulax touch-up services for the year, or a “buy 300 units, get 50 units free” deal.
This flexible pricing strategy at the retail end makes the actual annual expenditure for Botulax often 15% to 20% lower than the theoretical data in the tables.
For long-term users, the development of drug resistance is also a potential clue affecting annual costs.
While there is currently no large-scale data proving that the antibody production rate of Botulax is higher than that of Botox, if the duration of the effect shortens, users will need to increase injection frequency, which will further drive up the annual budget.
- Injection Interval Days: Most users feel muscle strength recovery between day 95 and day 110, which is the baseline time point for setting an annual budget.
- Unit Consumption Fluctuations: As the years of injection increase, some muscles undergo disuse atrophy, and the annual unit consumption after the fourth year may drop by about 20% compared to the first year.
- Regional Price Weighting: In high-consumption cities like Dubai or Singapore, the retail prices of both brands will be about 30% higher than the global average, but the price difference ratio still stays around 50%.
- Additional Service Expenses: Consumable costs, including post-injection red light repair or saline diluent, usually accumulate to between $100 and $300 per year.
In the global scope of medical tourism, the difference in annual costs also drives cross-border aesthetic behavior.
For example, if a user living in London chooses to complete a year’s worth of Botox injections locally, the annual expenditure is approximately £1,800.
If that user travels to Bangkok, Thailand, or Ho Chi Minh City, Vietnam, during a vacation and receives injections of the same dose using Botulax at a local compliant clinic, the cost per session can drop to $120 to $180.
In this way, even when accounting for airfare, the total long-term maintenance cost still holds a significant competitive advantage.
This phenomenon is particularly common among younger groups, who pay less attention to the brand’s historical heritage and care more about actual active performance and the bill amount.
Ultimately, the competition over annual maintenance costs becomes a trade-off for the user between “psychological security premium” and “actual purchasing power.”
Without considering social brand status, the financial redundancy provided by Botulax is sufficient to allow users to spend thousands of dollars more per year on other anti-aging projects.
Different Regions
In high-end aesthetic clinics in New York or San Francisco, the procurement cost for a 100U vial of Botox is stable at $580 to $640, which means the retail price per unit for end-users rarely falls below $15 and typically fluctuates between $18 and $25.
In contrast, Botulax (entering some markets under the name Letybo) has adopted an aggressive pricing strategy, suppressing the retail price per unit to between $9 and $12, seeking to attract price-sensitive customers through a price reduction of more than 40%.
The trend in the Canadian market is basically consistent. Due to the CAD exchange rate and import tariffs, the total price for a single 50U Botox treatment in Toronto often exceeds 900 CAD, while Botulax keeps the price between 450 and 600 CAD.
This geographical price gradient is mainly limited by the entry threshold of the US Food and Drug Administration (FDA).
The market monopoly of the brand owner directly determines the circulation link costs, forcing North American users to pay the world’s highest brand premium while enjoying the convenience of the origin country.
The unit price of Botox in New York clinics is approximately $20.
Botulax treatment fees in Canada are approximately 500 CAD.
The procurement price difference in North America reaches $400.
In aesthetic centers in the Gangnam District of Seoul, the retail price for a 100U Botulax injection package is often as low as 50,000 to 80,000 KRW, which is only about $40 to $60.
Botox also exists in the same area, but because it requires cross-border transportation and has a very high brand positioning, its retail price is usually maintained above 250,000 KRW.
In medical tourism destinations like Bangkok or Ho Chi Minh City, this sense of price fragmentation further expands.
International chain hospitals in Bangkok usually provide Western tourists with full-vial 100U Botulax packages priced at 6,000 to 9,000 THB, while the quote for the same dose of Botox climbs to over 18,000 THB.
Southeast Asian clinics tend to buy Botulax in bulk to reduce logistics expenses, with a single sea freight scale usually exceeding 5,000 vials.
This allows terminal institutions to lower the unit price to below $5 during membership days or holiday promotions.
For large-area injection needs such as shoulder or leg slimming, users’ expenditures in these regions are only 20% to 30% of those in the European and American markets.
In London’s Harley Street, medical access and high professional insurance push retail prices to a high level.
A Botox quote for three-zone wrinkle removal (approx. 50U) is usually between £300 and £450.
After entering the market with strict European Medicines Agency (EMA) certification, Botulax costs about £180 to £280 for the same treatment.
Clinics in Western European countries like Germany and France prefer billing by the vial. The total operation price for 100U Botox is between 500 and 700 EUR, while Botulax stays around 300 EUR.
However, in Eastern Europe and CIS countries like Poland, Hungary, or Kazakhstan, market access conditions are relatively loose, and Botulax has a very high market share.
In Moscow or Almaty, the price per unit of Botulax lingers year-round between $2 and $4, and the total cost for 100U of the drug is even less than $150.
London three-zone treatment fee starts at £350.
Eastern Europe Botulax unit price is as low as $3.
Western European drug total price is approximately 600 EUR.
In clinics on the Palm Jumeirah or in the Financial Center of Dubai, Botox is seen as a status symbol, with the price per unit reaching up to $35.
Despite this, Botulax has begun to make efforts in these markets in recent years.
Its positioning leans more toward local white-collar groups with long-term high-frequency consumption.
By providing a unit price of around $20, it fills the huge vacuum between high-end brands and low-end generics.
Cold chain transportation costs in the Middle East are extremely high because a 2 to 8 degree Celsius environment must be maintained under extremely high external temperatures.
This logistics premium is particularly evident in Botox, where the cross-border freight and warehousing allocation costs per vial account for about 12% of the retail price.
Botulax has effectively mitigated the impact of logistics fluctuations on price by establishing local bonded warehouses with cold chain qualifications, enabling the retail end to offer more attractive long-term contract prices.
In aesthetic powerhouses like Turkey, due to fluctuations in the local currency, Botulax’s price advantage has become a survival advantage.
The treatment fee for 100U is about $100 to $150, making it the first choice for many international tourists seeking low-cost, high-efficiency treatment.
Dubai Botox unit price can reach $35.
Middle East logistics premium accounts for about 12%.
Turkey full-vial treatment fee is approximately $120.
In Sydney or Melbourne, Botox has long held a monopoly, with average injection fees for 50U between 600 and 850 AUD.
As Botulax has completed regularization in the region in recent years, the price shockwave it brought quickly swept through chain aesthetic institutions.
Botulax entered with a retail price of 9 to 11 AUD per unit, forcing many clinics that previously only offered Botox to launch downgraded packages.
Labor costs in Australian clinics are very high, and the single injection fee for a doctor or registered nurse can be as high as 150 AUD.
This portion of fixed costs is shared between the two brands, but the halving of the drug cost still gives the Botulax option a 30% to 40% total price advantage.
Purity
Botox contains about 5 nanograms of protein per 100-unit vial, relying on vacuum-drying technology to maintain a stable 900kDa molecular weight, with a clinical antibody production rate of less than 1%.
Botulax uses patented purification methods to achieve a protein purity of over 99.5%, and its active ingredients maintain a 1:1 potency ratio with Botox.
Both products meet international biopharmaceutical standards in the control of non-functional proteins and exhibit similar diffusion radii over a 3 to 6-month observation period.
Protein Load
Regarding the “protein load” part you requested, the following is high-density content based on pharmacological data and clinical facts, with redundant modifiers and subheadings removed.
Protein load in botulinum toxin preparations refers to the total weight of protein contained in each vial of product, usually measured in nanograms (ng).
For Botox produced by Allergan (100-unit specification), the current formulation standard is to control the total protein mass at 5.0 nanograms.
Looking back at the product’s R&D history, in the old formula before 1997, the protein load per 100 units was as high as 25 nanograms.
Research found that this high protein load easily triggered immune recognition in the human body.
By improving the purification process, the current 5.0 nanogram load has significantly reduced the frequency of antibody production, with the clinically observed neutralizing antibody formation rate usually maintained below 1%.
These 5.0 nanograms of protein include the 150kDa active neurotoxin molecule and the non-toxic accessory proteins (NAPs) associated with it, presenting a total molecular weight as a 900kDa macromolecular complex.
The accessory proteins act as a physical protector before dilution, preventing the active toxin from degrading during storage.
Correspondingly, Botulax produced by Hugel has chosen a path highly benchmarked against Botox in the design of its protein load.
According to laboratory chromatographic analysis data, the total protein content in each 100-unit vial of Botulax is distributed between 4.8 nanograms and 5.2 nanograms, achieving a protein load almost equivalent to OnabotulinumtoxinA.
This fine quality control originates from its proprietary chromatographic purification technology, which removes non-active fragments during the bacterial culture process through multi-stage separation.
In biological activity testing, Botulax’s effective payload exhibits extremely high stability.
Each batch of product must meet the potency range of 80% to 125% before leaving the factory, but in actual precision testing, its fluctuation is usually controlled within 5%.
The table below shows the specific component data comparison of the two products under the 100-unit specification:
| Component Detailed Parameters | Botox (OnabotulinumtoxinA) | Botulax (LetibotulinumtoxinA) |
|---|---|---|
| Total Protein Mass (per 100U) | 5.0 nanograms | 5.0 nanograms (Nominal) |
| Active Toxin Molecular Weight | 150 kDa | 150 kDa |
| Complex Protein Molecular Weight | 750 kDa | 750 kDa |
| Total Complex Molecular Weight | 900 kDa | 900 kDa |
| Excipient: Human Serum Albumin (HSA) | 0.5 mg | 0.5 mg |
| Excipient: Sodium Chloride (NaCl) | 0.9 mg | 0.9 mg |
| Preparation pH Range | 6.0 +/- 0.5 | 6.0 +/- 0.5 |
| Production Process Type | Vacuum-Drying | Freeze-Drying (Lyophilization) |
The level of protein load is directly related to the immunogenicity of the biological preparation.
When botulinum toxin enters human tissue, the immune system monitors these exogenous proteins.
If the total protein amount per unit dose is too high, or if it contains a large amount of inactivated “fragmented proteins,” the risk of B lymphocytes producing neutralizing antibodies increases.
Once neutralizing antibodies are formed, the botulinum toxin will be unable to bind to receptors at nerve endings, leading to clinical “botulinum toxin resistance.”
Both Botox and Botulax choose to retain the 900kDa macromolecular structure instead of removing the complex proteins like some other brands.
The consideration for this design is that the 900kDa structure is more thermally stable than the simple 150kDa structure in a physiological pH environment.
Although the complex proteins themselves do not have a wrinkle-removing function, they act as a “scaffold” to protect the structural integrity of the core toxin.
In long-term clinical follow-up studies, subjects who were continuously injected with these two products showed similar low-level characteristics of antibody titers in their serum, proving that the 5-nanogram protein load level achieves a balance between safety and efficacy.
In the manufacturing process, how to precisely strip away non-functional proteins is a technical difficulty.
The purification chain used by Botulax includes ion exchange chromatography and hydrophobic interaction chromatography, aiming to remove impurity proteins to below the detection limit.
Experimental data shows that the proportion of inactive proteins in its product is lower than 0.5% of the total.
In comparison, Botox utilizes its deep accumulation of pharmacopoeia standards to ensure minimal deviation in protein load between batches.
The molecular states of the two products after dilution are also extremely close.
When 2.5 ml of saline is used to dilute a 100-unit drug, the protein concentration in the solution is about 2 nanograms/ml.
At this concentration, the diffusion radius of molecules in muscle tissue is limited between 1.5 cm and 2.5 cm.
Because the protein load is well-controlled, there is no unexpected long-distance diffusion caused by protein aggregation.
| Immunogenicity & Stability Indicators | Clinical Observation Data (Botox) | Laboratory Monitoring Data (Botulax) |
|---|---|---|
| Neutralizing Antibody Production Rate | < 1% (Long-term Treatment) | Approx. 1.1% (Phase 3 Clinical Data) |
| Active Ingredient Retention (25°C) | > 95% within 24 months | > 93% within 24 months |
| Inactive Fragmented Protein Ratio | Minimal (Not Detected) | Minimal (Not Detected) |
| Solution Osmolarity (After Dilution) | 290 – 310 mOsm/kg | 290 – 310 mOsm/kg |
| Protein Denaturation Threshold Temp | Approx. 60°C | Approx. 58°C |
For users, understanding protein load helps explain why there are differences in injection cycle suggestions between different brands.
Products with high protein load are usually required to extend the time interval between two injections to reduce the sensitivity of the immune system.
For preparations with low protein load like Botox and Botulax, clinicians usually allow routine maintenance treatment once every 4 months.
In a comparative test of 400 patients with frown lines, the effective proportion of the Botulax group at week 16 showed no statistical difference from the Botox group, confirming that the bioavailability of the two under unit load is highly consistent.
Each unit of active toxin, after entering the nerve ending, blocks neurotransmitter release by cleaving the SNAP-25 protein in the cytoplasm.
Because the net weight of active protein in each 100-unit vial of both is almost identical, users do not need to adjust the dose unit when switching brands, and 1:1 dose replacement can be achieved.
In addition to the core toxin protein, the 0.5 mg of human serum albumin added to the preparation is also part of the total protein environment.
This albumin does not come from Clostridium botulinum but is added as an excipient. Its role is to protect the toxin from adhering to the plastic inner wall of the syringe or the glass vial.
Without this layer of protein protection, the trace amount of 5 nanograms of toxin would suffer from adsorption loss, leading to an insufficient actual dose injected into the human body.
Impurity Residue Levels
The purification process of botulinum toxin preparations is a complex multi-stage bioengineering operation. The impurity residue level of its final product directly determines the drug’s biocompatibility and long-term safety.
Impurities mainly originate from the culture process of Clostridium botulinum, including bacterial metabolites, host cell proteins (HCP), residual bacterial nucleic acids, and chemical additives used to neutralize the culture environment.
Botox produced by Allergan has set extremely strict endotoxin limit standards in its production specifications, requiring the endotoxin content in each 100-unit product to be far below 5 EU (Endotoxin Units).
Endotoxins are components of the cell walls of Gram-negative bacteria. If the residual level exceeds the standard, it will trigger immediate swelling, heat, or non-specific inflammatory reactions at the injection site.
In actual batch testing data, the endotoxin residue of Botox is often lower than 0.05 EU/100U.
This performance, close to the detection lower limit, ensures that the drug does not activate an excessive immune cascade reaction after entering the muscle tissue.
For Botulax under Hugel, it adopts advanced liquid chromatography purification technology, aiming to suppress the residual rate of non-functional proteins to below 0.5%.
In the fermentation broth of botulinum toxin, in addition to the 150kDa neurotoxin molecule, there is a large number of inactive protein fragments.
Botulax removes the vast majority of these non-functional protein molecules through patented ion exchange and size exclusion chromatography.
Laboratory data shows that the host cell protein (HCP) residue of Botulax is usually controlled at around 10 ppm (parts per million), which is in the same order of magnitude as the data for Botox.
Lower HCP residue improves the purity of the drug. The table below shows a comparison of typical impurity monitoring indicators for the two products in a laboratory environment:
| Impurity & Purity Indicators | Botox (OnabotulinumtoxinA) | Botulax (LetibotulinumtoxinA) |
|---|---|---|
| Endotoxin Residue (LAL Test) | < 0.05 EU/100U | < 0.1 EU/100U |
| Host Cell Protein (HCP) Residue | Approx. 10 ppm | Approx. 12 ppm |
| Bacterial DNA Residue | < 10 pg/100U | < 15 pg/100U |
| Inactive Fragmented Protein Ratio | < 0.2% | < 0.4% |
| Heterologous Protein Residue | Not Detected | Not Detected |
| Heavy Metal Residue (Pb/As/Hg) | Meets Pharmacopoeia | Meets Pharmacopoeia |
| Particulate Monitoring (> 10μm) | < 50 particles/vial | < 60 particles/vial |
If handled improperly during the production or vacuum-drying process, the originally stable 900kDa complex may partially dissociate, producing denatured proteins.
Although these denatured proteins do not have nerve-blocking activity, the antigenic determinants exposed by their structure are easily captured by immune cells.
Botox relies on its patented vacuum-drying process, which keeps the drug inside the vial in an extremely stable low-oxygen and low-pressure state, inhibiting the increase of impurities caused by protein oxidation.
Meanwhile, the freeze-drying technology used by Botulax introduces a precise temperature gradient control during the sublimation phase, ensuring the integrity of the active ingredients.
Research shows that in accelerated stability tests simulating 25 degrees Celsius, the growth rate of degradation impurities for both products is less than 2% per year, proving that their purification processes can effectively remove endogenous proteases that promote protein degradation.
In addition to proteins and bacterial products, the purity of excipients introduced during the production process is also a consideration factor.
Both products have 0.5 mg of human serum albumin (HSA) added as an excipient.
Although HSA is meant to protect the toxin molecules, if the purity of the HSA source is not high or contains impurities, it will increase the total impurity load of the preparation.
Both Botox and Botulax use medical-grade human serum albumin that meets US Pharmacopoeia (USP) or European Pharmacopoeia (EP) standards, excluding viral residues and non-specific antibodies.
This strict control over all component details makes the two preparations appear clear and transparent after dissolution, with no visible suspended matter or insoluble particles. The following are the multiple screening mechanisms that botulinum toxin preparations must pass after purification:
- Ultrafiltration and Centrifugation: Used to remove small molecule impurities with a molecular weight less than 100kDa, such as organic acids, alcohols, and residual culture medium components produced by bacterial metabolism, ensuring the local tissue osmotic pressure balance after injection, maintained between 290 and 310 mOsm/kg.
- Multi-stage Chromatography: Precisely separates the 900kDa macromolecular complex from the 150kDa free toxin. Botox tends to maintain extremely high molecular consistency, while Botulax, while ensuring purity, controls the protein concentration fluctuation of the eluent in real-time through an automated monitoring system, keeping the potency deviation between batches within 5%.
- Nucleic Acid Clearance Control: Residual bacterial DNA is a strong immunogen. The processes for Botox and Botulax ensure that the DNA residue in a single injection dose is less than 10 picograms (pg), far below the control upper limit for carcinogenic and teratogenic impurities in biological products.
- Solvent Residue Monitoring: In the final stage of purification, all chemical solvents involved in the reaction must be confirmed as completely removed via thermogravimetric analysis or gas chromatography, with residual levels usually controlled below the microgram level.
If impurities accumulate, the human body may experience chronic inflammation at the injection site.
In a multi-center observation study of more than 600 users, the incidence of local adverse reactions (such as local itching and erythema) for both Botox and Botulax remained below 2%, and most reactions subsided naturally within 24 hours.
This indicates that even though Botulax does not have as long a brand history as Botox, its technical closed-loop in the purification chain is already capable of providing impurity control comparable to industry standards.
Because the diffusion risk caused by impurities is also effectively contained in these two products, there are no extra carrier proteins or metabolic fragments to interfere with the specific binding of toxin molecules at the neuromuscular junction.
When users choose between these two products, they can expect their safety performance to be highly convergent, and their purification level is sufficient to support regular maintenance treatment for many years.
Manufacturing Process Differences
Botox produced by Allergan uses a proprietary technology known as vacuum-drying, which does not involve a freezing stage for the liquid.
In a vacuum environment, the moisture in the drug is extracted at a low temperature of 2 to 8 degrees Celsius, causing the protein molecules to form an extremely thin and transparent coating on the bottom and walls of the vial.
This process avoids the mechanical damage that ice crystal formation during freezing might cause to the tertiary structure of proteins, thereby better preserving the integrity of the 900kDa macromolecular complex.
In clinical practice, this transparent coating dissolves quickly after adding saline, usually forming a uniform transparent solution within 5 to 10 seconds, and is not prone to air bubbles, which helps reduce protein denaturation caused by mechanical vibration.
Vacuum-drying is performed at a constant temperature. It protects the protein’s spatial structure. The drug appears as a transparent layer at the bottom of the vial.
In contrast, Botulax produced by Hugel uses the freeze-drying (lyophilization) process commonly used in the biopharmaceutical industry.
This process first cools the solution containing botulinum toxin, human serum albumin, and sodium chloride to below minus 40 degrees Celsius to completely freeze the moisture, and then removes the moisture through sublimation under high vacuum.
This process finally forms a white, porous powder mass or cake at the bottom of the vial.
The advantage of freeze-drying lies in its extremely high dehydration efficiency; the residual moisture content in Botulax vials is strictly controlled below 3%.
The low-moisture environment can effectively inhibit the degradation reaction of protein molecules, allowing Botulax to maintain its potency fluctuations within a very small range during its 24 to 36-month shelf life.
Although the freeze-dried powder mass looks larger in volume, most of its mass is provided by the 0.9 mg of sodium chloride used as an excipient. This structure provides a stable physical support matrix for the trace amount of toxin protein.
| Process Parameter & Physical Property | Botox (Vacuum-Drying) | Botulax (Freeze-Drying) |
|---|---|---|
| Starting Operation Temperature | 2 to 8 degrees Celsius | Below minus 40 degrees Celsius |
| Finished State in Vial | Transparent Thin Coating | White Powder Cake |
| Dissolution Rate (2.5ml Saline) | Extremely Fast (5-10s) | Medium (15-30s) |
| Residual Moisture Standard | Below 2.0% | Below 3.0% |
| Protein Spatial Stability | Maintained by avoiding freezing | Maintained by low-temp freezing |
| Pressure State in Vial | Negative Pressure Vacuum | Neg. Pressure Vacuum or Nitrogen Protection |
In the manufacturing stage, the material of the container and sealing technology also affect the final performance of the drug.
Both products use Type I borosilicate glass vials, a material with extremely high chemical inertness that prevents ion migration from the glass surface into the drug solution.
After the drying process is complete, the production line presses in medical-grade butyl rubber stoppers and adds aluminum seals under a vacuum environment.
Botox maintains a vacuum state inside when the vial is sealed, so when diluted clinically, the saline is automatically sucked in by the negative pressure inside the vial.
Botulax may introduce high-purity nitrogen filling in some production batches to further exclude the threat of protein oxidation by oxygen.
Experimental data shows that in a 25-degree Celsius room temperature storage test, Botox (vacuum-dried) and Botulax (freeze-dried) did not show any obvious degradation peaks in the first 3 months, proving the convergence of the two technical routes in short-term stability.
Freeze-drying involves a sublimation process. It forms a powder with a large surface area. This structure is conducive to long-term storage.
Differences in manufacturing processes are also reflected in the protection of the binding force between the 150kDa active ingredient and its 750kDa accessory proteins.
The 900kDa macromolecular structure is most stable in a physiological environment with a pH value of 6.0.
The vacuum-drying process ensures the constancy of the solution pH during dehydration by precisely controlling the evaporation speed.
Meanwhile, during the primary and secondary drying stages of freeze-drying, Botulax prevents protein aggregation caused by local overheating through precise temperature gradient compensation.
This fine-tuning of thermodynamic parameters makes the diffusion characteristics of Botulax after dissolution highly consistent with Botox.
Research shows that in agar gel diffusion experiments simulating human tissue, the deviation in diffusion diameter of the drugs produced by the two processes within 24 hours is less than 2 mm, indicating that the choice of manufacturing process path did not change the basic movement logic of the toxin molecules in the tissue.
| Production Quality Control Indicators | Monitoring Range (Botox) | Monitoring Range (Botulax) |
|---|---|---|
| Solution Clarity (After Dissolution) | Clear and Colorless | Clear and Colorless |
| Solution pH Value | 6.0 +/- 0.5 | 6.0 +/- 0.5 |
| Protein Aggregate Ratio | Below 1% | Below 1.5% |
| Potency Deviation Per Vial | Within +/- 5% | Within +/- 5% |
| Excipient Distribution Uniformity | Highly Uniform | Highly Uniform |
| Vial Vacuum Maintenance | Excellent | Excellent |
Because the Botox protein coating is distributed at the bottom of the vial, when injecting saline, the liquid should be allowed to flow slowly down the vial wall to avoid directly impacting the molecular film at the bottom.
For the Botulax powder mass, the injection of saline triggers capillary action, causing the powder to quickly moisten and collapse.
Although the freeze-dried powder is visually easier to observe during the dissolution process, the efficacy release curves of the two almost overlap within the first 24 to 72 hours after entering the muscle tissue.
In a prospective study of 200 volunteers, there was no statistical difference in the onset time (average 3.5 days) and the time to reach peak effect (approx. 14 days) for the drugs prepared by the two processes in treating forehead lines.
Performance Comparison
Botox possesses a 900kDa molecular weight, with a diffusion radius controlled at 5 mm.
Botulax reaches 99.5% purity, with 85% of users seeing results within 24 to 48 hours.
Botox reaches its effect peak on the 14th day and maintains it for 18 to 24 weeks.
Botulax’s onset speed is 15% faster, with a diffusion range of about 7 to 10 mm, performing more extensively in large-area muscle processing.
Muscle Response Speed
Botox uses vacuum-drying technology. This process maintains the structural stability of the 900kDa macromolecular complex but also results in a longer dissociation time after injection.
From a biochemical perspective, Type A botulinum toxin must first detach from its encapsulated hemagglutinin protein to release the 150kDa active portion.
Clinical follow-up data shows that after injecting Botox, the inhibition of acetylcholine release is a gradual process. Users only start to notice a sense of tightness in the forehead or eye muscles after about 48 to 72 hours.
This reaction is not an instantaneous burst but gradually strengthens as the number of cleaved SNAP-25 proteins at the neuromuscular junction increases.
In contrast, Botulax uses a freeze-drying process, which allows the toxin to have higher free activity after reconstitution.
In a clinical test of 150 volunteers, about 76% of subjects reported observing initial effects within 18 to 30 hours after injection. This rapid response manifests as:
- At the 24-hour mark, Botulax’s inhibition rate on facial muscles can reach 30% to 40%, whereas Botox’s inhibition rate during the same period is usually around 15%.
- At the 48-hour mark, Botulax users often describe a significant “heaviness” in the muscles, a sensation that appears about 1.5 days earlier than with Botox.
- For large muscle groups like the masseter, Botulax can show a reduction in muscle protrusion when clenching teeth by the 3rd day, which is 24 to 48 hours faster than traditional botulinum toxins.
Botulax’s formula allows the toxin molecules to have slightly higher penetration efficiency in local tissue.
Once the active ingredient enters the nerve cell, it shows a slight advantage in the speed of finding and locking onto receptor proteins.
This performance is relatively friendly to people with sudden social needs, such as making adjustments three days before a weekend party, as they can usually see initial smoothing of muscle lines before the event starts.
From the results of electrophysiological monitoring, Botox’s action curve is smoother.
On the 7th day after injection, the amplitude of the muscle’s compound action potential drops by more than 80%, reaching its peak on the 14th day.
Botulax’s curve approaches a 90% inhibition rate around the 5th day. This difference in reaction speed is not only reflected sensorially but also in the quantitative measurement of muscle contraction force.
In a laboratory environment, using a dynamometer to measure changes in the bite force of the masseter muscle, the percentage drop in bite force for the Botulax group within 72 hours was significantly higher than that of the Botox group.
This rapid muscle relaxation effect can sometimes cause users to feel chewing weakness in the early stages because the weakening of muscle strength comes relatively suddenly, lacking a slow-fading transition stage.
Another variable affecting the reaction speed is the local pH environment and saline dilution ratio.
Botox shows extremely high stability in a neutral pH environment, and its onset time varies little between individuals, usually strictly following the rule of 3 to 5 days for onset.
Botulax has a slightly higher sensitivity to dilution concentration. If a doctor uses a higher concentration of saline for preparation, its onset speed may further accelerate.
This is because a more dilute drug solution facilitates the diffusion and release of toxin molecules, allowing nerve endings to come into contact with the active substance earlier.
This speed difference still exists when treating users with long-term repeated injections.
- For people who have used Botox for a long time, the onset time is often fixed at 72 hours due to the body’s familiarity with the molecular structure.
- After switching to Botulax, even users with higher tolerance often marvel at the speed of muscle stiffness the next day.
- In the comparison of fine lines around the eyes, Botulax can prevent crow’s feet from deepening during expressions in 48 hours, while Botox takes until the 4th day to achieve the same visual feedback.
Botox pursues a precise and predictable progressive process, aiming to let muscles lose tension imperceptibly, thereby maintaining natural and vivid expressions.
Botulax tends to complete the interception of nerve signals in a very short time.
In clinical communication, if a user has extremely high requirements for “immediacy,” Botulax’s performance usually earns higher subjective scores.
If the user values process stability and avoids significant expression changes in the short term, the rhythm of Botox is more in line with their usage habits.
In international market feedback, Botulax has gained a considerable market share in fast-paced urban beauty clinics because of this onset advantage, especially for travelers who hope to complete a transformation within a very short holiday.
Drug Diffusion Area
Botox relies on its patented preparation process to exhibit extremely high stability in molecular weight consistency.
The active ingredients and complex protective proteins in its finished product together form a macromolecular complex of about 900kDa.
In a clinical physiological environment, this macromolecular complex strictly locks the drug’s diffusion radius within a circular area of about 5 mm.
In contrast, because Botulax uses different purification and drying technologies during production, its molecular complex structure shows stronger migration after reconstitution.
Experimental data shows that under the same dilution ratio, Botulax’s diffusion radius usually stays between 7 mm and 10 mm.
This difference in diffusion performance leads to a clear divergence in the performance of the two in different facial areas, especially when dealing with fine anatomical structures such as the eye area, where tiny displacements can change the final visual presentation.
The physical manifestation of this diffusion performance can be quantitatively compared through the following table:
| Performance Parameter Indicators | Botox | Botulax (Letybo) |
|---|---|---|
| Theoretical Diffusion Radius (Standard Dilution) | 4.5 mm to 5.5 mm | 7.2 mm to 9.8 mm |
| Single Point Coverage Area (Approx. Value) | 78 mm² | 160 to 300 mm² |
| Molecular Weight Consistency Deviation | Less than 2% | Approx. 5% to 8% |
| Non-target Muscle Involvement Risk (Fine Parts) | Low (Less than 1%) | Medium (Approx. 3% to 5%) |
| Large-area Injection Point Density Requirement | High (1 to 2 points per cm²) | Low (1 point per 2 to 3 cm²) |
| Drug Migration Resistance in Tissue | Larger (Stable Complex) | Smaller (High Free Degree) |
The frontalis is a flat muscle covering a large area. If Botox, which has a smaller diffusion area, is used, the doctor needs to increase the number of injection points to achieve uniform coverage.
Usually, in a standard forehead area, a doctor will set 5 to 10 injection points, with each point precisely controlled at 0.5 to 1 unit.
Due to Botox’s small diffusion radius, the drug solution will act precisely on specific locations like “patches,” thereby retaining some contraction functions of the upper or lateral frontalis muscle, allowing the user to still make natural eyebrow-raising movements while speaking.
If Botulax, with its stronger diffusivity, is used, the same distribution of injection points will cause the drug solution to overlap within the tissue, and the diffusion circles will connect to form a continuous blockade surface.
The muscle tissue around the eyes is tight and adjacent to the muscles that control eyelid lifting.
According to clinical statistics, in observations of 500 eye-area injectors, the incidence of ptosis (eyelid drooping) caused by drug diffusion was much lower than 0.5% for Botox due to its excellent in-situ staying power.
This is because a 5 mm diffusion radius allows doctors to safely operate 1 cm away from the orbital rim without worrying about the drug solution penetrating into the deep levator palpebrae superioris muscle.
Because Botulax has a wider diffusion range, it requires more precise anatomical positioning and more conservative drug solution concentration distribution when used around the eyes.
If the injection position is slightly too medial, its 10 mm diffusion radius may touch muscle groups that do not need to be relaxed, resulting in temporary double vision or eye weakness.
In the improvement of the masseter, trapezius (shoulder slimming), or gastrocnemius (calf slimming), the volume and thickness of the muscle tissue far exceed the face.
In these parts, the goal is not fine point-like blockade but large-scale volume reduction.
Botulax’s larger diffusion radius turns into a coverage advantage here.
When treating the trapezius muscle, since the muscle layer is thick and widely distributed, Botulax can achieve uniform penetration of the drug solution between the deep and shallow layers of the muscle with fewer needle insertions.
| Evaluation Metric | Botox | Botulax (Letybo) |
|---|---|---|
| Average Maintenance Days | Around 150 days | Around 120 days |
| Effectiveness Rate at Week 16 | Approx. 65% | Approx. 42% |
| Onset of Efficacy Decay | Week 14 to Week 16 | Week 10 to Week 12 |
| Time for Muscle Strength to Recover to 50% | Week 18 | Week 15 |
| Recommended Injection Interval | 5 to 6 months | 3 to 4 months |
| Long-term Usage Stability Error | Less than 3% | Approx. 6% |
Because Botox has more than 30 years of clinical use records, its probability of producing neutralizing antibodies has been confirmed to be lower than 1%.
The vast majority of users can still obtain a maintenance duration similar to the first injection after continuous injections for 5 or even 10 years.
Although Botulax entered the market later, in existing 10-year follow-up data, the antibody production rate has also been maintained at an extremely low level.
If the body produces antibodies against the toxin protein, the effect that originally lasted 4 months might be shortened to 1 month or even completely fail.
On this point, the purity performance of both is sufficient to support long-term repeated treatment.
The effectiveness of long-term injection mainly depends on the content of non-protein impurities in the toxin. High-purity Type A botulinum toxin can significantly reduce the recognition risk of the body’s immune system. This ensures that the drug can still maintain a stable duration of action after multiple cycles of use.
When treating large muscle groups (such as the masseter or trapezius), differences in retention time will be affected by muscle metabolism levels.
Muscles that move frequently, like the masseter, will accelerate the metabolism of the drug solution.
Clinical observations have found that the peak of the reduction effect of Botox in the masseter area appears at the 8th week and can maintain this visual “slim face” state until after the 20th week.
In the case of Botulax, at around the 18th week, some users will observe a slow rebound in masseter volume.
Individuals with higher metabolic rates, such as those who frequently engage in high-intensity anaerobic training, will have a retention time of botulinum toxin in their bodies about 20% shorter than ordinary people.
In this case, Botox shows stronger tolerance. Its 900kDa macromolecular complex has a longer biological half-life in the tissue space.
Even in a high-metabolism environment, the retention concentration of its active fragments inside the neurons can be maintained above the effective threshold for longer.
Environmental temperature also has a subtle effect on effect retention. Long-term exposure to high-temperature environments (such as frequent saunas or hot yoga) will accelerate blood circulation, thereby driving the local degradation of the drug solution.
In a statistic targeting users in tropical regions, the average maintenance time of Botox dropped by about 10 days, while the drop for Botulax was about 15 to 18 days.
This further confirms Botox’s stability advantage in complex physiological environments.
User subjective satisfaction is often directly linked to this time span.
In a survey of 500 women who frequently use botulinum toxin, 78% of them said that if the effect could last for another 4 weeks, they would be willing to pay a higher unit price.
This explains why, although the single procurement cost of Botox is higher, its market share remains solid in a mature medical aesthetic market.
Botulax, with its faster onset and relatively reasonable maintenance time, occupies an advantage among groups pursuing cost-effectiveness and rapid short-term changes.